May 2024 in “European urology focus” In this systematic review and meta-analysis, the authors found no statistically significant association between the use of 5α-reductase inhibitors and the risk of depression or suicide among over two million studied patients.
December 2022 in “JAMA network open” This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.
9 citations
,
April 2020 in “The Journal of Urology” This study found that initiation of 5α-reductase inhibitors like finasteride is not associated with an increased risk of depression in veterans, suggesting depression may be linked to underlying health conditions instead.
90 citations
,
March 2017 in “JAMA Internal Medicine” In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.
4 citations
,
May 2019 in “The World Journal of Men's Health” This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.